{
    "organizations": [],
    "uuid": "444094fe7b4999e696d0d9b9015dc2a9d06a5e88",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-bavarian-nordic-collaboration-to-e/brief-bavarian-nordic-collaboration-to-evaluate-cv301-in-combination-with-durvalumab-idUSASM000JPU",
    "ord_in_thread": 0,
    "title": "BRIEF-Bavarian Nordic: Collaboration to Evaluate CV301 in Combination with durvalumab",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 26 (Reuters) - Bavarian Nordic A/S:\n* REG-BAVARIAN NORDIC ANNOUNCES COLLABORATION TO EVALUATE CV301 IN COMBINATION WITH DURVALUMAB IN COLORECTAL AND PANCREATIC CANCERS\n* ‍BAVARIAN NORDIC AND ASTRAZENECA WILL CONTRIBUTE CLINICAL TRIAL MATERIAL AND PROVIDE FINANCIAL SUPPORT FOR PHASE 1/2​\n* ‍NEW COLLABORATION THAT WILL INVESTIGATE CV301 AND DURVALUMAB (IMFINZI(TM))​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)\n ",
    "published": "2018-02-26T17:43:00.000+02:00",
    "crawled": "2018-02-27T15:03:03.016+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "bavarian",
        "nordic",
        "nordic",
        "announces",
        "collaboration",
        "evaluate",
        "cv301",
        "combination",
        "durvalumab",
        "colorectal",
        "pancreatic",
        "cancer",
        "nordic",
        "astrazeneca",
        "contribute",
        "clinical",
        "trial",
        "material",
        "provide",
        "financial",
        "support",
        "phase",
        "collaboration",
        "investigate",
        "cv301",
        "durvalumab",
        "imfinzi",
        "tm",
        "source",
        "text",
        "eikon",
        "company",
        "coverage",
        "gdynia",
        "newsroom"
    ]
}